New products from Lilly
Eli Lilly and Company (LLY) has launched various products under different franchises. A few of its new products include Portrazza, Cyramza, Basaglar, Jardiance, Taltz, and Trulicity.
Portrazza is a new drug for the treatment of metastatic squamous NSCLC (non-small cell lung cancer). The drug was launched in December 2015 after the FDA (US Food and Drug Administration) approved the drug on November 24, 2015. Portrazza reported sales of $5.3 million in 3Q16.
This drug’s sales reached $4.8 million in US markets, while the drug was launched in the European markets in 2Q16 and reported $0.5 million in 3Q16.
Other drugs in the oncology field include Pfizer’s (PFE) Inlyta and Sutent, Bristol-Myers Squibb’s (BMY) Opdivo, Merck’s (MRK) Keytruda, GlaxoSmithKline’s (GSK) Mekinist and Tafinlar, and Roche’s Zelboraf.
Lilly launched Taltz in US markets in April 2016, and then launched the drug in European markets in July 2016. In 3Q16, Taltz revenues were $33 million, which consisted of $32 million in sales from US markets.
Basaglar is an insulin glargine injection that controls blood sugar levels in patients with type-1 and type-2 diabetes. Basaglar is expected to be launched in US markets in December 2016. Lilly reported Basaglar sales of $19 million in 3Q16 from Japan and a few European markets.
Jardiance is another drug from Lilly meant to lower blood sugar levels in patients with type-2 diabetes. Jardiance is part of the Boehringer Ingelheim and Lilly diabetes alliance. The revenues reported for the drug reached $47 million for 3Q16, as compared to $15 million for 3Q15.
Cyramza is an oncology drug used in combination with other drugs for the treatment of metastatic NSCLC, advanced gastric cancer, and metastatic colorectal cancer. Cyramza sales rose 43% in 3Q16 to $159 million, due to rising demand in Japan and European markets for the treatment of metastatic NSCLC and metastatic colorectal cancer.
Trulicity is a drug that improves blood sugar levels in patients with type-2 diabetes. Trulicity reported sales of $244 million in 3Q16, as compared to $74 million in 3Q15. This rise was mainly due to higher demand in US markets, where the drug reported sales of $189 million in 3Q16.
Remember, to divest risk, investors can get exposure to companies like Lilly through ETFs like the iShares Morningstar Large Core ETF (JKD), which has 1.3% of its total portfolio invested in Lilly.